Navidea Biopharmaceuticals (NYSE:NAVB) Research Coverage Started at StockNews.com
StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research report report published on Wednesday morning. The brokerage issued a sell rating on the stock. Navidea Biopharmaceuticals Stock Performance NYSE:NAVB opened at $0.00 on Wednesday. Navidea Biopharmaceuticals has a 1-year low of $0.00 and a 1-year high of $0.13. The […]
More Stories
US Coast Guard Operation Seizes 150,000 Pounds of Cocaine
By Naveen Athrappully More than 150,000 pounds of cocaine have been seized in the Eastern Pacific Ocean since the launch...
Number of Americans Receiving Unemployment Benefits Falls to 10-Month Low
By Andrew Moran The number of Americans collecting unemployment benefits has slipped to its lowest point in 10 months, the...
US Trade Deficit Unexpectedly Falls to 5-Year Low as Exports Surge
By Andrew Moran President Donald Trump’s tariffs helped shrink the U.S. trade deficit to its lowest monthly level in more...
CDC Advisers Turn Focus to Aluminum in Vaccines
By Zachary Stieber A common adjuvant in vaccines is under scrutiny by a panel that has initiated multiple changes to...
7 Best TextNow Alternatives for Free Calling in 2026
Free calling apps like TextNow are being widely used today for smooth global communication without needing extra hardware and software....
Trump Says US Has Seized Oil Tanker Off Coast of Venezuela
By Jack Phillips President Donald Trump said on Dec. 10 that the United States seized an oil tanker off the...